UBS Group’s iShares Biotechnology ETF IBB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $847K | Hold |
5,014
| – | – | ﹤0.01% | 5675 |
|
|
2025
Q4 | $846K | Buy |
5,014
+2,764
| +123% | +$449K | ﹤0.01% | 5714 |
|
|
2025
Q3 | $325K | Sell |
2,250
-6
| -0.3% | -$819 | ﹤0.01% | 6380 |
|
|
2025
Q2 | $285K | Buy |
+2,256
| New | +$277K | ﹤0.01% | 6475 |
|
|
2025
Q1 | – | Sell |
-93,800
| Closed | -$12.4M | – | 10448 |
|
|
2024
Q4 | $12.4M | Buy |
+93,800
| New | +$13.2M | ﹤0.01% | 2826 |
|
|
2023
Q3 | – | Sell |
-9,800
| Closed | -$1.24M | – | 9678 |
|
|
2023
Q2 | $1.24M | Buy |
+9,800
| New | +$1.27M | ﹤0.01% | 4026 |
|
|
2023
Q1 | – | Sell |
-303,621
| Closed | -$39.9M | – | 9927 |
|
|
2022
Q4 | $39.9M | Buy |
303,621
+3,621
| +1% | +$468K | 0.01% | 937 |
|
|
2022
Q3 | $35.1M | Hold |
300,000
| – | – | 0.02% | 901 |
|
|
2022
Q2 | $35.3M | Buy |
+300,000
| New | +$35.6M | 0.01% | 947 |
|
|
2022
Q1 | – | Sell |
-50,000
| Closed | -$7.63M | – | 10522 |
|
|
2021
Q4 | $7.63M | Buy |
+50,000
| New | +$7.74M | ﹤0.01% | 2391 |
|
|
2020
Q4 | – | Sell |
-100,000
| Closed | -$13.5M | – | 8544 |
|
|
2020
Q3 | $13.5M | Buy |
+100,000
| New | +$13.6M | 0.01% | 1438 |
|
|
2020
Q2 | – | Sell |
-11,400
| Closed | -$1.23M | – | 8125 |
|
|
2020
Q1 | $1.23M | Sell |
11,400
-1,218,500
| -99% | -$140M | ﹤0.01% | 3180 |
|
|
2019
Q4 | $148M | Buy |
1,229,900
+845,900
| +220% | +$94.4M | 0.05% | 329 |
|
|
2019
Q3 | $38.2M | Buy |
384,000
+198,100
| +107% | +$20.7M | 0.01% | 835 |
|
|
2019
Q2 | $20.3M | Sell |
185,900
-112,300
| -38% | -$11.9M | 0.01% | 1211 |
|
|
2019
Q1 | $33.3M | Buy |
298,200
+144,900
| +95% | +$15.9M | 0.01% | 844 |
|
|
2018
Q4 | $14.8M | Buy |
153,300
+150,900
| +6,288% | +$16M | 0.01% | 1290 |
|
|
2018
Q3 | $293K | Sell |
2,400
-37,000
| -94% | -$4.36M | ﹤0.01% | 4771 |
|
|
2018
Q2 | $4.33M | Sell |
39,400
-31,300
| -44% | -$3.35M | ﹤0.01% | 2463 |
|
|
2018
Q1 | $7.55M | Buy |
70,700
+22,700
| +47% | +$2.52M | ﹤0.01% | 1933 |
|
|
2017
Q4 | $5.13M | Buy |
48,000
+39,900
| +493% | +$4.26M | ﹤0.01% | 2335 |
|
|
2017
Q3 | $901K | Buy |
+8,100
| New | +$866K | ﹤0.01% | 3791 |
|
|
2017
Q2 | – | Sell |
-195,000
| Closed | -$19.1M | – | 7797 |
|
|
2017
Q1 | $19.1M | Buy |
195,000
+59,100
| +43% | +$5.66M | 0.01% | 1059 |
|
|
2016
Q4 | $12M | Buy |
135,900
+130,500
| +2,417% | +$11.9M | 0.01% | 1361 |
|
|
2016
Q3 | $521K | Sell |
5,400
-26,700
| -83% | -$2.54M | ﹤0.01% | 3900 |
|
|
2016
Q2 | $2.75M | Buy |
32,100
+29,400
| +1,089% | +$2.64M | ﹤0.01% | 2497 |
|
|
2016
Q1 | $235K | Buy |
2,700
+1,800
| +200% | +$161K | ﹤0.01% | 4377 |
|
|
2015
Q4 | $102K | Sell |
900
-7,950
| -90% | -$863K | ﹤0.01% | 5188 |
|
|
2015
Q3 | $895K | Sell |
8,850
-172,050
| -95% | -$20.6M | ﹤0.01% | 3455 |
|
|
2015
Q2 | $22.2M | Buy |
180,900
+114,600
| +173% | +$13.7M | 0.01% | 905 |
|
|
2015
Q1 | $7.59M | Sell |
66,300
-55,800
| -46% | -$6.15M | 0.01% | 1703 |
|
|
2014
Q4 | $12.3M | Buy |
+122,100
| New | +$11.9M | 0.01% | 1344 |
|
Other funds holding IBB
CB
UBS Group's IBB Position: Q1 2026 in Review
UBS Group reduced its iShares Biotechnology ETF (IBB) stake by 11% in Q1 2026, selling an estimated $16.9M and leaving 814,290 shares worth $137M. The position accounts for 0.02% of the portfolio, ranked #818.
UBS Group first reported a position in IBB in Q4 2014 and has held it in 46 quarters since. The position peaked at $629M in Q2 2019. 917 funds tracked by Wall St. Rank hold IBB as of Q1 2026.
- UBS Group held 814,290 shares of iShares Biotechnology ETF worth $137M as of Q1 2026.
- UBS Group sold 98,745 iShares Biotechnology ETF shares in Q1 2026, an estimated $16.9M.
- iShares Biotechnology ETF made up 0.02% of UBS Group's portfolio in Q1 2026, its #818 holding.
- UBS Group first reported a position in iShares Biotechnology ETF in Q4 2014 and has held it in 46 quarters since.
- UBS Group's iShares Biotechnology ETF position peaked at $629M in Q2 2019.
- 917 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.